Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2024 results topping the market’s revenue expectations, with sales ...

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...

Sugar can lead to high blood sugar and contributes to the development of diabetes.

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

Living with Type 1 diabetes is a numbers game. There’s not a moment in the day free from the burden of tracking your blood ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...